Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

Authors not listed

Regeneron Pharmaceuticals · 2025

Abstract

This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice. The main objective is to describe demographic and clinical characteristics of patients receiving aflibercept 2mg injections, to estimate the incidence of RV and RV plus Intraocular Inflammation (IOI) following aflibercept 2mg injections and to describe characteristics of RV cases.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Anonymous. (2025). Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study. <em>Regeneron Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT07105228
Vancouver
Anonymous. Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study. Regeneron Pharmaceuticals. 2025.
BibTeX
@misc{anon2025Incide, title = {Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study}, author = {Anonymous}, journal = {Regeneron Pharmaceuticals}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings